Market Overview

Slayback Pharma Appoints Dr Girish Jain as Head of Global R&D


Slayback Pharma Appoints Dr Girish Jain as Head of Global R&D

PR Newswire

PRINCETON, N.J., July 24, 2018 /PRNewswire/ -- Slayback Pharma LLC ("Slayback"), a privately held pharmaceutical research and development company, announced today the appointment of Dr Girish Jain as Senior Vice President and Head of Global R&D. Dr Jain will be based out of Slayback's Hyderabad, India office.

(PRNewsfoto/Slayback Pharma LLC)

Dr Jain is a highly accomplished scientist and a veteran in the field of Pharmaceutical Research and Development. He is widely recognized in India for his R&D leadership. He has successfully led the development and filing of more than 225 ANDAs with USFDA, across various dosage forms and over 75 different products with Europe and Australia. He is also the lead inventor in scores of granted patents. His experience straddles both the innovative and generic pharmaceutical research space.

Dr Girish Jain has had a stellar leadership track record in the industry. Prior to joining Slayback, he was President and Head of R&D at Alkem for the last four years. Earlier, he served for 10 years at Wockhardt where he was the Senior Vice President and Head of R&D in his last position.

While welcoming Dr Jain to Slayback, Ajay Singh, President & CEO, said, "Girish is both an excellent scientist and an inspiring leader. He leads from the front and rolls up his sleeves to get the work done. I am delighted to have Girish join us to inspire and lead our motivated R&D team."

"I am very excited to work with highly motivated team of Slayback and expect to achieve greater heights for the organization working together with the team," said Dr Jain.


Slayback is a New-Jersey based pharmaceutical company focused on the development of complex generic and specialty pharmaceutical products.

Cision View original content with multimedia:

SOURCE Slayback Pharma LLC

View Comments and Join the Discussion!